Objective. To investigate whether patients with RA enrolled in randomized controlled trials (RCTs) and observational studies may differ in terms of characteristics that could modify treatment effects, leading to an efficacyeffectiveness gap.
Introduction
The randomized controlled trial (RCT) is the gold standard for assessing the efficacy of pharmacological treatments and other interventions [1] . The main advantage of random treatment allocation is the high internal validity of estimates of treatment effects. Estimates from RCTs may, however, lack external validity [2] due to their highly standardized design, strict inclusion and exclusion criteria, and fixed treatment regimens that may often be at odds with real world conditions [3, 4] .
In health technology assessment it is essential to gauge the effectiveness of drugs in the real world settings where they will be used [5] . Several authors have recommended using non-randomized studies, clinical databases and registry data (i.e. observational studies) to assess whether RCT-based estimates apply to a target population [58] . Patient characteristics may differ between RCTs and observational studies, and may modify treatment effects [7] . A treatment may be less effective or more effective depending on age, stage of disease or comorbidities [811] . For example, studies comparing treatment effects between RCTs and observational studies in cardiovascular disease showed that patients with acute coronary syndrome included in clinical trials were younger, more likely to be men, and had fewer co-morbidities and risk factors when compared with registry patients [12, 13] . Similar results were found by Ezekowitz and colleagues [14] , who compared characteristics of patients with heart failure between RCTs and observational studies. In this context Eichler and colleagues [8] coined the term efficacyeffectiveness gap to describe the gap between treatment effects observed in RCTs and those observed in real world settings.
A comparison of baseline characteristics of patients with RA in RCTs and observational studies is lacking. We performed a systematic review extracting baseline characteristics from available RCTs and observational studies in RA. This review was a deliverable of Workpackage 4 of the GetReal project (incorporating real-life data into drug development), a consortium of academia, pharmaceutical companies, health technology assessment agencies, regulators and patient organizations [15] . Using case studies, WP4 developed best practices in evidence synthesis and predictive modelling, with the goal of improving estimates of the real world effectiveness of drugs by incorporating the results of RCTs with other sources of clinical data, including observational data. WP4 obtained access to individual participant data from clinical trials of three widely used biologics, namely etanercept (ETN), rituximab (RTX) and tocilizumab (TCZ), as well as patient registries in RA. Our systematic review thus also focused on ETN, RTX and TCZ.
Methods

Search strategy
We performed two systematic reviews: one literature search was done for observational studies, the other for RCTs. We applied study design search filters from the BMJ Evidence Centre Information Specialists to the EMBASE and MEDLINE databases using Ovid [16] . We performed the search for observational studies on 4 March 2015, and the search for RCTs on 24 April 2015. The detailed search strategies can be found in supplementary Tables S1S4, available at Rheumatology
Online. In addition, we manually searched known registries and screened reference lists of all papers.
Inclusion criteria and study selection
We included studies of adult patients diagnosed with RA who were treated with RTX, TCZ or ETN. Studies were required to have reported the following outcomes: DAS-28, including CRP (DAS-28-CRP) or ESR (DAS-28-ESR), or HAQ-Disability Index (HAQ-DI) scores. The studies had to include at least 30 patients per study arm.
The retrieved titles and abstracts of the identified articles were imported into EppiReviewer 4 [17] . Duplicates across databases were removed, and for each treatment, the latest publication fulfilling the inclusion criteria was used. Each paper was independently assessed by two reviewers (G.K. and N.H. or G.K. and E.D.), based on title and abstract and, if the study was potentially eligible, on the full text of the article. Disagreements were resolved by consensus, after discussion with M.E. or S.R. whenever necessary.
Data extraction
Data from each included paper were extracted using a standardized form developed for this project. Extracted data covered three areas: first, general data included author, publication year, study design, country, overall number of patients in the study, follow-up time and the main objective of the study; second, treatment data included drug, dose, frequency and route of administration; and third, data on patient characteristics at baseline included number of patients receiving each drug, age, gender, current smoking, disease duration, comorbidities, ESR, CRP, seropositivity for RF or ACPA, DAS-28 and HAQ-DI, switching from another biologic agent to the current drug, number of prior DMARDs and use of corticosteroids and other drugs. We extracted dichotomous data as numbers and percentages. For continuous data, we extracted the mean or median, together with the standard deviation or range (minimum/maximum or interquartile range).
Statistical analysis
We converted medians and ranges to means (S.D.) using the methods described by Wan et al. [18] . For binary data we used the variance estimator (v) for proportions (p) to derive the standard error: v = p(1 p). We performed metaanalyses of patient characteristics separately for RCTs and observational studies, overall and by drug. If necessary, we first combined the data from the study arm into a single mean or proportion using fixed-effect meta-analyses. Secondly, we combined the data separately for RCTs and observational studies using random-effects meta-analyses with the KnappHartung adjustment [19] . We used mixed-effects meta-regression analyses to assess the differences in patient characteristics between RCTs and observational studies by including the study design as a dichotomous covariate. We used restricted maximum-likelihood estimation to assess between-study variance (tau-squared) and applied the KnappHartung adjustment. We stratified our main analysis by study type to explore whether the approaches differed in terms of baseline characteristics. In further meta-regression analyses, we included the year of publication of the studies to examine whether patient characteristics of patients included in RCTs or observational studies changed over calendar time. In a sensitivity analysis, we excluded phase IV and pragmatic trials, as reported by the trialists. All analyses were done with the R package metaphor [20] .
Results
We identified 308 references in our literature search for RCTs and 594 for observational studies, and considered 89 RCTs and 194 observational studies to be potentially eligible (supplementary Figs S1 and S2, available at Rheumatology Online). Fifty-one RCTs and 76 observational studies met our inclusion criteria and were included in the meta-analysis.
Study characteristics
The Tables 1 and 2 summarize characteristics of RCTs and observational studies.
Comparison of patient characteristics
Compared with patients participating in RCTs, those from observational studies were on average 3.0 years older (P < 0.001), suffered from RA for 3.1 years longer (P < 0.001) and had 1.6 more prior DMARDs (P = 0.001; Fig. 1 ). Patients in RCTs had higher disease activity: the DAS-28 was 0.6 points higher in RCT than in observational studies (P < 0.001; Fig. 2 ). CRP and ESR levels were also slightly higher in RCTs, but differences failed to reach conventional levels of statistical significance (Fig. 2) . Similarly, there was little evidence for any difference between HAQ-DI scores, RF positivity or the proportion of women participating in the studies. Analyses stratified by drug showed that differences generally were in the same direction for the three drugs, but tended to be more pronounced for TCZ and RTX than for ETN (Figs 1 and 2) . Patients on TCZ were 3.9 years older in observational studies than in RCTs (P < 0.001), their disease duration was 2.4 years longer (P = 0.06), they had been exposed on average to 1.4 additional DMARDs (P = 0.346) and the DAS-28 was 1.2 points lower than in RCTs (P < 0.001). Similarly, patients on RTX were 3.3 years older (P = 0.013), their disease duration was 2.6 years longer (P = 0.05), they had been exposed to 1.8 more DMARDs (P = 0.083) and the DAS-28 was 1.1 points (P < 0.001) lower in observational studies than in RCTs. Patients on ETN were 2.4 years older in observational studies than in RCTs (P = 0.017), their disease duration was 3.4 years longer (P < 0.001) and they had been exposed to 1.6 more DMARDs (P = 0.056). There was no difference in DAS-28 (0 points, P = 0.86). Analyses stratified by study type gave similar results compared with the main analyses (supplementary Figs S3S11, available at Rheumatology Online, forest plots for all baseline characteristics).
Trends over calendar time
We found that DAS-28 declined over calendar time both in RCTs (slope of À0.08, P = 0.026) and in observational studies (slope of À0.08, P = 0.002) (Fig. 3) . HAQ-DI declined slightly over calendar time both in RCTs (slope of À0.04, P = 0.004) and in observational studies (slope of À0.04, P = 0.063) (Fig. 4) . Furthermore, ESR and CRP declined over calendar time in RCTs (slope of À1.69, P = 0.009 for ESR and slope of À1.68, P = 0.001 for CRP), but not significantly so in observational studies (supplementary Figs S16-S17). There was little evidence for changes in baseline patient characteristics over time for any of the other sociodemographic or clinical characteristics (supplementary Figs S12S15, available at Rheumatology Online).
Sensitivity analysis
In a sensitivity analysis we excluded 10 phase IV trials and 1 pragmatic trial. Ten of the excluded trials included patients on ETN, while one trial included patients on TCZ.
There was no substantial change compared with the main analyses, except that ESR increased from 46.3 to 49.4 mm/h in RCTs, which is significantly higher than in observational studies (P = 0.004).
Discussion
In this study of the characteristics of patients with RA we found clinically relevant differences between RCTs and
RCT: randomized controlled trial; OBS: observational study.
https://academic.oup.com/rheumatology observational studies in RA. Compared with RCTs, RA patients in observational studies were older, disease duration was longer, a higher number of different DMARDs were administered before starting biologic treatment and disease activity was lower at baseline. Over time, baseline DAS-28 and HAQ-DI declined in patients included in RCTs but not in patients from observational databases.
FIG. 2 Comparison between randomized controlled trials and observational studies: DAS-28, HAQ, CRP, ESR and RF positivity
Differences between real-world and trial data are important, especially when making decisions in everyday clinical practice. Eichler and colleagues [8] argue that the efficacyeffectiveness gap is due to variability in drug response caused by biological and behavioural factors. Biological factors can be separated into genetic and non-genetic factors, which in turn can be further divided into intrinsic and extrinsic factors. Intrinsic factors are characteristics of the person such as age, sex, body weight, comorbidities and baseline severity of disease, whereas extrinsic factors relate to lifestyle factors such as smoking [8] .
Kirsch and colleagues studied all available data of clinical trials submitted to the Food and Drug Administration for the licensing of four new-generation antidepressants [9] . They found a relationship between initial disease severity and anti-depressant efficacy, an association that was due to decreased responsiveness to placebo among very severely depressed patients as opposed to increased responsiveness to medication. Similarly, in patients with RA a high DAS-28 score at baseline is a good predictor of a decline in the DAS-28 following treatment with ETN [148] and TCZ [120] . Our review showed higher DAS-28 scores in patients enrolled in RCTs and we can therefore speculate that the response was better in trial patients than in observational studies. In other words, the treatment effect in everyday clinical praxis might be smaller than that in RCTs.
High numbers of prior DMARDs and higher age were associated with decreased response rates in patients with ETN [149] . Older age was also associated with decreased response rate in age with TCZ [150] ; these two baseline characteristics differed significantly between RCTs and observational studies in our analysis. Predictive factors for better response to biologics were male gender (in ETN-treated patients [149] ), non-smokers (ETN [149] ), RF positivity (RTX and TC [151] ) and low HAQ-DI (TCZ [120] and RTX [149] ). For all these factors, if data were available, we found no difference between RCTs and observational studies.
In our time trend analysis, we saw a decrease in baseline DAS-28 and HAQ-DI in RCTs over the past 10 years. A decrease in DAS-28 has also been shown for other biologics such as infliximab [152] . These findings support the results of an inception cohort study published 10 years ago, where the trend was thought to be caused by a more aggressive treatment strategy [153] .
In a sensitivity analysis we excluded 10 phase IV clinical trials and one pragmatic trial. Interestingly, we found no difference compared with the main results described   FIG. 3 Comparison of DAS-28 between randomized controlled trials and observational studies plotted over time https://academic.oup.com/rheumatology above. In particular, the results in the ETN group where 10 trials were excluded remained virtually the same. This may call into question the notion that phase IV trials accurately represent real-world scenarios, and that their estimates of comparative effectiveness are closer to those of observational studies. We acknowledge that the number of phase IV and pragmatic trials was small and that the results from our sensitivity analysis should be interpreted with caution.
Our review has several strengths and weaknesses. Strengths are that the review was based on a systematic literature search, and study selection and screening were performed independently by two authors. Data extraction was performed by one person and checked by a second. Our search was comprehensive, but we included only English-language studies. Also, we did not look into reports by the European Medicines Agency or Food and Drug Administration. Data for each biologic may have been assessed at different time points in each registry. For instance, in the Rabbit registry, we used data for ETN from 2006, whereas data for RTX was assessed from a publication in 2013. We cannot exclude the possibility that some of the included patients were counted twice, because patients might have switched their treatment from ETN to RTX. However, in the absence of individual patient data we can only speculate the percentage of patients who switched treatment regimens. Overall, 7 of the 28 included registries had more than one publication, and it is therefore possible that patients were counted twice.
Since we did not assess outcomes, we did not apply any risk of bias tool or similar instrument to examine the quality of studies. Our main interest was the   FIG. 4 Comparison of HAQ disability index between randomized controlled trials and observational studies plotted over time characteristics of patients included in RCTs and observational studies and it is therefore unlikely that the comparison was distorted by publication or other selection bias.
We transformed median values into mean values. This might lead to bias in the aggregated mean if the data summarized by the median were clearly not normally distributed. Since we transformed only about 8% of the values provided in the RCTs and only about 17% of the values from the observational studies, any bias introduced is likely small. Several relevant variables were poorly reported: concomitant MTX use, concomitant DMARD use, percentage of smokers (reported in only one RCT), comorbidities and ACPA positivity. These variables were therefore not included in our analyses, despite their potential relevance in the context of generalizing results from RCTs to real world settings.
Clearly, more work is required on how best to narrow the efficacyeffectiveness gap. In phase IV and pragmatic trials, inclusion and exclusion criteria need to be widened to reflect the real world. The baseline characteristics of patients included in these trials should better reflect what we found in observational studies. In addition, evidence synthesis and modelling approaches should be used to combine data from both RCT and observational studies to generate real-world evidence [15] .
In summary, we found important differences between RA patients included in RCTs as compared with observational studies; in particular, patients with better prognostic factors were included in the RCTs, leading to potential overestimation of the treatment effect. More research is needed to overcome this efficacyeffectiveness gap in RA to generate real-world evidence. 
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